Ads
related to: regeneron- Contact Us
Find all the ways to reach us
for the information you need.
- Our Company
Learn about our mission and
the values that drive us.
- News
Stay current on all things Vertex
and discover the latest news.
- Our Unique Approach
See What Makes Us Unique
And How We Put Science First.
- Contact Us
Search results
Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) the Best Bet in Gene Therapy Industry?
Insider Monkey via Yahoo Finance· 2 days agoWe recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we...
FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
Zacks via Yahoo Finance· 5 days agoPer the FDA, the data submitted by Sanofi (SNY)/Regeneron (REGN) for Dupixent in COPD indication...
Navigating 14 Analyst Ratings For Regeneron Pharmaceuticals - Regeneron Pharmaceuticals...
Benzinga· 19 hours agoLoading... Loading... Throughout the last three months, 14 analysts have evaluated Regeneron Pharmaceuticals REGN , offering a diverse set of opinions from bullish to bearish ...
Leonard Schleifer
Fortune· 21 hours agoRegeneron is a research-oriented biotech, founded by Schleifer, that had no product on the market for its first 20 years. Today its monoclonal antibodies, particularly Eylea ...
What's Going On With FibroGen Stock Tuesday? - FibroGen (NASDAQ:FGEN)
Benzinga· 15 hours agoFibroGen also announced a new clinical trial supply agreement with Regeneron. The Details: FibroGen...
FDA delays decision on Dupixent in COPD; Summit makes a bold claim
BioPharma Dive via Yahoo Finance· 5 days agoRegeneron and Sanofi now expect an FDA verdict in September. Elsewhere, Summit claimed victory over...
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type...
Morningstar· 5 days agoRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by three months the target action date of ...
FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
Benzinga via Yahoo Finance· 5 days agoOn Friday, the FDA extended the target action date of priority review of supplemental application...
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate...
Benzinga· 2 days agoFibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO® in patients with select solid tumorsFibroGen to evaluate FG-3175,
Health Care Stocks Show Relative Strength as S&P 500 Stalls
Zacks via Yahoo Finance· 14 hours agoRegeneron Pharmaceuticals REGN is breaking out of a cup-with-handle base, pushing up against...
Ad
related to: regeneron
